Colorectal Cancer

As new therapies enter the treatment landscape for metastatic colorectal cancer, oncology nurses become even more critical in educating patients about side effects and the importance of reporting adverse events promptly.

The NCNN recommends testing for Lynch syndrome for at-risk individuals, regardless of whether they have colorectal cancer.

When deciding on a cancer treatment—and determining its effectiveness—look for a biomarker.

Recent studies show that two common colorectal cancer screening practices are both effective.

The genetic disease, Lynch syndrome, can significantly increase the risk of colon and other cancers.

In the right cancer, radiation and chemotherapy can make a powerful duo.

Despite advances in drugs for metastatic colorectal cancer, the disease is still most successfully treated when detected early, while it is within the confines of its original location.

Genetic targets have led to better treatments for advanced colorectal cancer.

The latest in cancer prevention, diagnosis & treatment.

Advances in ostomy care and maintenance have resulted in more normal lives following colorectal cancer surgery.

Updates from the American Society of Clinical Oncology meetings on genitourinary and gastrointestinal cancers.

Regorafenib shows to extend survival in metastatic colorectal cancer.

Ginger has been investigated for its anti-nausea proper ties, and it’s back in the news as a possible preventive for colon cancer.

A new study published in The Lancet shows that one group could reduce their risk of colorectal cancer from taking the pill on a daily basis.

Recent studies link vitamin D and folate intake to colon cancer risk reduction.

ColoPrint gene assay can help guide treatment options for some colorectal patients, study shows.

Widespread genetic testing of Lynch syndrome is cost-efficient and reduces the risk of colorectal cancer.

A growing population of patients have emerged: long-term metastatic cancer survivors.

The latest in cancer prevention, diagnosis, and treatment.

Early-stage colorectal cancer patients may benefit from a new test that predicts their risk of recurrence.

Chronic inflammation causes cancer. Find out how and what's being done about it.

What does Medicare cover when it comes to screening for colorectal cancer?

Despite the gains noted in the overall number of Medicare patients undergoing colonoscopy, researchers continue to see differences in colorectal cancer screening rates among certain groups, particularly minorities.

Newer targets found on cancer cells are providing scientists the ammunition to better treat cancer.

Adding Avastin (bevacizumab) to standard chemotherapy after surgery failed to extend the time early-stage colon cancer patients were free of recurrence.

For the first time, a test can predict which patients with stage 2 colon cancer are more likely to have a recurrence.

Gene testing now recommended before colon cancer treatment

Treatment updates from the 2009 ASCO Gastrointestinal Cancers Symposium.

New colorectal cancer screening gets high marks.